The Plukett 316/99

IN THE UNITED STATES RATENT AND TRADEMARK OFFICE

FEB 25 1999 10

develvel

APPLICANT:

Johannsson et al

MAR 1 1999

SERIAL NO:

09/050,366

GROUP NO: 1654

MATRIX JUST CUTER

FILING DATE:

March 31, 1998

EXAMINER: Moezie, F.

FOR:

Use of Growth Hormone

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97 AND 1.98

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. 1.56, the undersigned hereby submits the documents listed on the attached PTO-1449 for consideration by the Examiner in charge of the above-identified patent application.

[] U.S. patent applications which the applicant considers to be related to the above-identified application are as follows:

[] A concise explanation of the relevance of the non-English language references is as follows:

[] The relevance of the references is indicated on the enclosed copy of the Search Report for the priority application.

These documents are being submitted:

- [] within three months of the filing of the above U.S. national application, or of the date of entry of the U.S. national stage of an international patent application.
- 2. [x] before receiving a first Office Action on the merits of the above-identified patent application.
- 3. [] following receipt of a first Office Action but before issuance of a Final Action or a Notice of Allowance.
 - 4. [] following receipt of a Notice of Allowance, or a Final Office Action.

Petition

The undersigned hereby requests consideration of this information after mailing the Final Action or Notice of Allowance by the filing of this Petition under 37 C.F.R. 1.97(d)(2)(ii) and attaching a check in the amount of \$130 as the petition fee set forth in 37 C.F.R. 1.17(i)(l).

- A. [] A check in the amount of \$230 is attached in payment of the fee set forth in 37 C.F.R. 1.17(p).
- B. [] The undersigned certifies that each item of this information is being submitted within three months of the date it was cited by a foreign patent office in a counterpart application.

C. [] The undersigned certifies that, after making reasonable inquiry, he/she has no knowledge that any item of this information was cited by a foreign patent office in a counterpart application or was known more than three months prior to this submission.

The Commissioner is hereby authorized to charge payment of any deficiency in the above fee(s), or any additional fees required under 37 C.F.R. 1.16 or 1.17, or credit any overpayment, to Deposit Account No. 22-0185. A duplicate authorization is attached.

Respectfully subpritted,

Americk (24.852)

Pollock, Vande Sande & Amernick

P.O. Box 19088

Washington, D.C. 20036

(202) 331-7111